Physician profile
David Rich
NPI 1396732426
$2,377.85
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $494 · 2021: $618 · 2022: $497 · 2023: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.34 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.70 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $175.07 | 2021-2023 | Veozah |
| Abbvie INC. | $174.14 | 2021-2023 | |
| Novo Nordisk INC | $166.75 | 2019-2022 | |
| Dornier Medtech America, INC | $155.73 | 2021 | |
| Pfizer INC. | $128.99 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.60 | 2022 | |
| Amgen INC. | $111.69 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $104.43 | 2021-2023 | |
| Allergan, INC. | $99.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.97 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.98 | 2022-2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $81.55 | 2019-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $73.90 | 2020-2023 | Rexulti |
| Genentech USA, INC. | $66.75 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.73 | 2022-2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $60.52 | 2020-2021 | |
| Amarin Pharma, INC. | $55.35 | 2020-2021 | |
| Glaxosmithkline, LLC. | $52.56 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $51.43 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $33.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.20 | 2020-2021 | |
| Exact Sciences Corporation | $24.93 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $23.50 | 2020 | |
| Avanir Pharmaceuticals, INC. | $21.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.66 | 2022 | |
| Abbott Laboratories | $19.17 | 2022 | |
| Mylan Specialty L.P. | $17.96 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.18 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.02 | 2021 | |
| Lundbeck LLC | $15.87 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.62 | 2020 | |
| Eisai INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.